Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)

Sebelipase alfa for treating lysosomal acid lipase deficiency [ID737]: Notice of appeal

NICE has received 3 appeals against the Final Evaluation Determination on the above HST evaluation from the following organisations:

• Alexion Pharma UK
• MPS Society
• Birmingham Children’s Hospital NHS Foundation Trust                                                                                                                        

NICE also received 2 appeals, which were rejected at scrutiny stage from the following organisations:

• The British Inherited Metabolic Disease Group 
• Salford Royal Hospital NHS Foundation Trust

The Appeal hearing took place at NICE, 10 Spring Gardens, London, SW1A 2BU - 25 April 2017, 10am. NICE awaits the decision of the appeal panel. 

This page was last updated: 25 April 2017